NCT04726293 (MG2) is a NA clinical trial of Mango in Overweight or Obesity, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.

Who is sponsoring NCT04726293?

NCT04726293 is sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.

What drugs are being tested in NCT04726293?

Interventions in NCT04726293: Mango, Control.

What condition does NCT04726293 study?

NCT04726293 studies Overweight or Obesity, Healthy.

Is NCT04726293 still recruiting?

NCT04726293 is currently completed. Last updated 11 May 2025.

Last reviewed 2025-05-11 · How we verify

NCT04726293: MG2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-inflammatory Effect and Associated Mechanisms of Mango Consumption

Completed NA Last updated 11 May 2025

What this trial tests

NA trial testing Mango in Overweight or Obesity in 60 participants. Completed in 28 April 2025.

Timeline

22 February 2021

Primary endpoint
31 March 2023

28 April 2025

Quick facts

Lead sponsor	Clinical Nutrition Research Center, Illinois Institute of Technology
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	60
Start date	22 February 2021
Primary completion	31 March 2023
Estimated completion	28 April 2025
Sites	1 location across United States

Drugs / interventions tested

Mango
Control

Conditions studied

Overweight or Obesity — all drugs for Overweight or Obesity →
Healthy — all drugs for Healthy →

Sponsor

Clinical Nutrition Research Center, Illinois Institute of Technology — full company profile →

Who can join

Adults 20 to 60, any sex, with Overweight or Obesity or Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this project is to provide new knowledge through a comprehensive set of analyses that investigate the complex interplay between regular mango intake, gut microbial structure/ function, mechanisms of inflammation and insulin sensitivity in over weight (OW)/obese (OB) human subjects with chronic low-grade inflammation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The Regulatory Effect of Phytochemicals on Chronic Diseases by Targeting Nrf2-ARE Signaling Pathway.
He WJ, Lv CH, Chen Z, Shi M, et al · · 2023 · cited 46× · PMID 36829795 · DOI 10.3390/antiox12020236
Mango Consumption Is Associated with Increased Insulin Sensitivity in Participants with Overweight/Obesity and Chronic Low-Grade Inflammation.
Pett KD, Alex PG, Weisfuss C, Sandhu A, et al · · 2025 · cited 4× · PMID 39940348 · DOI 10.3390/nu17030490

Verify or expand the search:

Other trials of Mango

Trials testing the same drug.

NCT06986161 — Optimizing Mango's Glycemic Impact: Investigating Mango Consumption Timing in Prediabetic Individuals · NA · recruiting
NCT06800833 — Effects of Mango or Low-Fat Cookie Consumption on Gut Health, and Its Relationship With Mental, Sexual and Skin Health · NA · recruiting
NCT06029647 — Mangos to Reduce Cardiometabolic Risk Markers · NA · completed
NCT05571800 — Effect of Mango Consumption on Individuals with Pre-diabetes · NA · completed
NCT06055582 — To Study the Effects of Mango Ingestion in T2DM and Non-diabetic Subjects. · NA · completed

Other recruiting trials for Overweight or Obesity

Currently open trials in the same condition.

NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07431086 — Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US · Phase 2 · recruiting
NCT07294235 — A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants · Phase 1 · recruiting
NCT07224399 — Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multi · Phase 1 · recruiting
NCT07170319 — A Study of IBI3032 in Chinese Participants With Overweight or Obesity · Phase 1 · active not recruiting

Other Clinical Nutrition Research Center, Illinois Institute of Technology trials

Trials by the same sponsor.

NCT06986161 — Optimizing Mango's Glycemic Impact: Investigating Mango Consumption Timing in Prediabetic Individuals · NA · recruiting
NCT06555952 — MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors · NA · recruiting
NCT05898217 — Vitamin and Mineral Absorption From Milk and PBMAs · NA · active not recruiting
NCT05892328 — Watermelon Dose Response Blood Pressure Study · NA · active not recruiting
NCT05601635 — ButyraGen™, Short Chain Fatty Acids and Gut Microbiome · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04726293 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clinical Nutrition Research Center, Illinois Institute of Technology
Last refreshed: 11 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04726293.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing